Company intelligence / Profile preview

Injectsense

Emeryville, California, United States

Ownership: Private
Development stage: Other

Overview

Injectsense has completed its first human implantation of its ultraminiaturized intraocular pressure sensor for glaucoma, following established safety in 9-month animal studies with no adverse events. Data is continuously and wirelessly transmitted; human pilot is ongoing to generate first direct intraocular data.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Large ophthalmic strategic partnersManufacturing partners in US and Europe

Beyond the preview

Go deeper on Injectsense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Injectsense.

Explore the full profile